Lipid-conjugated siRNA targeting SARM1 enables CNS silencing and mitigates alzheimer-like phenotypes.
RNA interference (RNAi) therapeutics have achieved clinical success in liver disease, but their application to central nervous system (CNS) disorders remains limited. Here, we developed a lipid-conjugated siRNA to silence sterile alpha and TIR motif-containing protein 1 (SARM1), a key executor of axon degeneration asso...